258 related articles for article (PubMed ID: 32653925)
1. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.
Bordenave J; Thuillet R; Tu L; Phan C; Cumont A; Marsol C; Huertas A; Savale L; Hibert M; Galzi JL; Bonnet D; Humbert M; Frossard N; Guignabert C
Cardiovasc Res; 2020 Mar; 116(3):686-697. PubMed ID: 31173066
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
6. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension.
Nogueira-Ferreira R; Ferreira-Pinto MJ; Silva AF; Vitorino R; Justino J; Costa R; Moreira-Gonçalves D; Quignard JF; Ducret T; Savineau JP; Leite-Moreira AF; Ferreira R; Henriques-Coelho T
J Cell Physiol; 2017 Nov; 232(11):3128-3138. PubMed ID: 28036116
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Chrysant SG
J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
[TBL] [Abstract][Full Text] [Related]
8. Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration.
Luo S; Kan J; Zhang J; Ye P; Wang D; Jiang X; Li M; Zhu L; Gu Y
J Cardiovasc Pharmacol; 2021 Aug; 78(2):253-262. PubMed ID: 34554677
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension.
Chen X; Yu X; Lian G; Tang H; Yan Y; Gao G; Huang B; Luo L; Xie L
Biomed Pharmacother; 2024 May; 174():116505. PubMed ID: 38574614
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
[TBL] [Abstract][Full Text] [Related]
11. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin Attenuates Pulmonary Hypertension Through Inhibition of Pulmonary Vascular Remodeling in Rats.
Tang M; Wang R; Feng P; Dong Q; Chen W; Zhao Y; Li A; Li H; Chen J; Huang W
J Cardiovasc Pharmacol; 2020 Sep; 76(3):337-348. PubMed ID: 32569012
[TBL] [Abstract][Full Text] [Related]
13. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of dioscin on vascular remodeling in pulmonary arterial hypertension via adjusting GRB2/ERK/PI3K-AKT signal.
Yang Y; Yin L; Zhu M; Song S; Sun C; Han X; Xu Y; Zhao Y; Qi Y; Xu L; Peng JY
Biomed Pharmacother; 2021 Jan; 133():111056. PubMed ID: 33378960
[TBL] [Abstract][Full Text] [Related]
15. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells.
Price LC; Shao D; Meng C; Perros F; Garfield BE; Zhu J; Montani D; Dorfmuller P; Humbert M; Adcock IM; Wort SJ
Respir Res; 2015 Sep; 16(1):114. PubMed ID: 26382031
[TBL] [Abstract][Full Text] [Related]
18. Isoquercitrin protects against pulmonary hypertension via inhibiting PASMCs proliferation.
Zhang Y; Cui Y; Deng W; Wang H; Qin W; Huang C; Li C; Zhang J; Guo Y; Wu D; Guo H
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):362-370. PubMed ID: 27873355
[TBL] [Abstract][Full Text] [Related]
19. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]